Appointments to SCRI's drug development programme
This article was originally published in Scrip
Executive Summary
Sarah Cannon Research Institute has promoted Dr Jeffrey Infante to director of drug development in Nashville, US, while Dr Howard Burris will assume the role of executive director for the overall drug development programme. Dr Burris, SCRI's CMO, will provide executive oversight of the drug development programmes in Nashville, Oklahoma, Florida and London. Dr Infante previously served as associate director of the Nashville based drug development programme.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.